Ronco C, et al. ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells. MedChemComm. 2016 Nov 30;8(2):295-319.
 Brown JS, et al. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov. 2017 Jan;7(1):20-37.
 Cheng B, et al. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. Eur J Med Chem. 2022 Feb 15;230:114109.
 Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. Mol Cell. 2017 Jun 15;66(6):801-817.
 Roulston A, et al. RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors. Mol Cancer Ther. 2022 Feb;21(2):245-256.
 Yap TA, et al. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol. 2020 Sep 20;38(27):3195-3204.
 Harold J, et al. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecol Oncol. 2023 Jan;168:157-165.
 Kobayashi H, et al. Conceptual frameworks of synthetic lethality in clear cell carcinoma of the ovary. Biomed Rep. 2018 Aug;9(2):112-118.
 Yap TA, et al. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. Clin Cancer Res. 2021 Oct 1;27(19):5213-5224.
 Kwon M, et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. J Immunother Cancer. 2022 Jul;10(7):e005041.